ClinicalTrials.gg
RecruitingNCT07534852NIMAUpdated Apr 16, 2026

NIMA-Colon Cancer Study

An interventional study of Standard hypercaloric-hyperproteic nutritional supplementation and HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium in Colon Cancer, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jul 2025, registered Feb 2026).
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Colonic Neoplasms with a site in Spain — 33 open to participants now, 47 under way, 7 of them phase 3. Colonic Neoplasms · Spain.

Planned enrollment
53rd of 91
120 · median 155
Started
2025
with 9 others
No phase
25 of 121
7 open now
Primary completion
2027-08
later than 24 of 46 live
Registered
118th of 121
by date
Lead sponsor
2 of 121
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

Among the 121 studies in Colonic Neoplasms with a site in Spain, this one is the 53rd largest by planned enrollment of the 91 interventional ones that give a count, is one of 10 that started in 2025, is one of 25 with no phase, reaches primary completion later than 24 of the 46 other live ones, and was the 118th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

33 of the 121 studies in Colonic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Colonic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the effects of nutritional supplementation and physical activity interventions on recovery, muscle strength, nutritional status, inflammation, and metabolic health in adults with colon cancer undergoing surgery.

Patients with colon cancer frequently experience loss of muscle mass, reduced physical function, and nutritional deterioration both before and after surgery, which may adversely affect recovery and quality of life.

A key objective of this study is to assess whether a postoperative intervention combining nutritional supplementation with beta-hydroxy beta-methylbutyrate (HMB) and vitamin D, together with a structured physical activity program, can improve muscle strength and functional recovery following colon cancer surgery.

This study aims to answer the following questions:

  • Does nutritional supplementation with HMB and vitamin D, combined with postoperative physical activity, improve muscle strength and physical function following colon cancer surgery?
  • How do nutritional and lifestyle interventions influence nutritional status, gut microbiota composition, and biological markers of inflammation and metabolism during the recovery period?
  • Are there differences in recovery outcomes between patients receiving different types of nutritional support, with or without supervised physical activity?

Participants will be adults diagnosed with colon cancer who undergo surgical treatment at the Hospital Universitario Virgen de la Victoria in Málaga, Spain. Patients will be recruited prior to surgery and will enter a prehabilitation phase integrated into routine care provided by the Endocrinology and Nutrition Department.

During this prehabilitation phase, nutritional status will be assessed and optimized using standard clinical care, including oral nutritional supplementation when indicated. The aim is to improve the patient's condition before surgery. Approximately one month after surgery, once initial postoperative recovery has been completed, participants will enter the intervention and assessment phase (baseline visit).

Participants will then be randomly assigned to one of four study groups in a 2×2 factorial design. These groups combine two nutritional strategies (standard care or supplementation with HMB and vitamin D) and two physical activity approaches (supervised exercise or general activity recommendations). The physical activity component, supervised by the Endocrinology and Nutrition team, will be objectively evaluated using an accelerometer-based device. Participants will be followed for approximately six months, with assessments at about 3 and 6 months after the baseline visit.

At each visit, participants will undergo:

  • Body composition measurements
  • Muscle strength and physical performance tests
  • Collection of blood, urine, and stool samples
  • Questionnaires on health status and quality of life

The results of this study will contribute to a more profound understanding of how tailored nutritional strategies and postoperative physical activity may support recovery and functional health in patients undergoing surgery for colon cancer.

Read the detailed description

Colon cancer patients frequently present with nutritional impairment, systemic inflammation, and early loss of muscle mass even before surgical treatment. These conditions may be exacerbated by surgical stress, reduced intake, and postoperative physical inactivity, leading to delayed recovery, functional decline, and impaired quality of life. Interventions targeting nutritional and functional status across the perioperative period may help improve physiological reserve and support postoperative recovery.

The NIMA study (Nutritional, Inflammatory, and Muscular Assessment) is designed to evaluate the impact of perioperative nutritional care and postoperative physical activity strategies on recovery, muscle strength, nutritional status, inflammation, metabolic health, and gut microbiota in adults undergoing surgery for colon cancer. The study combines routine preoperative nutritional management with a structured postoperative intervention and follow-up period, allowing assessment of short- and medium-term changes during recovery.

Study Setting and Population: This study includes adult patients diagnosed with colon cancer stages I to III, (TNM classification) who undergo surgical treatment at the Hospital Universitario Virgen de la Victoria in Málaga, Spain. Participants are identified and recruited before surgery through standard clinical pathways. All participants provide written informed consent before enrollment. The study is conducted in accordance with ethical principles and has been approved by the appropriate ethics committee.

Prehabilitation Phase (Preoperative Nutritional Care): Approximately two weeks before surgery, patients undergo a prehabilitation phase integrated into routine clinical care provided by the Endocrinology and Nutrition Department. This phase includes assessment and optimization of nutritional status through clinical evaluation, follow-up, and oral hypercaloric and hyperproteic supplementation when indicated. The aim is to improve metabolic condition and physiological reserve prior to surgical stress.

Surgical Treatment and Standard Postoperative Care: All participants undergo standard surgical treatment and postoperative oncological management according to institutional clinical practice. Participation in the study does not modify surgical procedures, immediate postoperative care, or oncological treatment.

Postoperative Interventions(Factorial Design): Approximately one month after surgery, once initial postoperative recovery has been achieved, participants enter the intervention phase (baseline visit). Participants are randomly assigned to one of four study groups according to a 2×2 factorial design:

  • Standard nutritional care + general physical activity recommendations
  • Standard nutritional care + supervised exercise program
  • Enhanced nutritional supplementation (beta-hydroxy beta-methylbutyrate [HMB] and vitamin D) + general physical activity recommendations
  • Enhanced nutritional supplementation (HMB and vitamin D) + supervised exercise program Enhanced nutritional supplementation consists of HMB combined with vitamin D (and calcium, when applicable), administered in addition to standard nutritional care.

The supervised physical activity program consists of structured, progressive resistance and functional exercises adapted to each participant's postoperative condition, targeting major muscle groups to improve muscle strength and functional capacity. Participants assigned to general physical activity receive standard recommendations according to routine clinical practice. Physical activity levels are objectively assessed using a wearable accelerometer.

Follow-up and Assessments: Approximately one month after surgery, once initial postoperative recovery has been achieved, participants enter the intervention and assessment phase (baseline visit) and are followed for approximately six months, with follow-up assessments at around 3 and 6 months. A comprehensive morphofunctional evaluation is performed at baseline and repeated at 6 months, including body composition, muscle strength, functional performance, and nutritional assessment using techniques such as bioelectrical impedance analysis, nutritional ultrasound, and standardized functional tests. Additional strength and resistance tests are also conducted as part of the study-specific evaluations. Biological samples (blood, urine, and stool) are collected at predefined time points to assess metabolic, inflammatory, and microbiota-related parameters. At the 3-month visit, a partial assessment is carried out, including selected clinical, functional, and questionnaire-based measures(including validated questionnaires assessing health status, quality of life, dietary intake, physical activity levels, and psychological well-being), allowing evaluation of both short- and medium-term changes during postoperative recovery. For participants assigned to the structured and supervised physical activity program, physical activity adherence, intensity, and patterns are objectively monitored using a wearable accelerometer, which is worn for 7 consecutive days monthly throughout the follow-up period, providing quantitative data on real-world physical activity behavior.

Study Relevance: By integrating perioperative nutritional care with structured postoperative interventions within a factorial design, the NIMA study aims to determine the independent and combined effects of nutritional supplementation and physical activity on recovery. The findings may contribute to optimizing perioperative care and improving functional outcomes in patients undergoing colon cancer surgery.

03

Conditions studied

  • Colon Cancer

Keywords

  • Colon cancer
  • Nutritional supplementation
  • Physical activity
  • Muscle strength
  • Inflammation
  • Gut microbiota
  • Beta-hydroxy beta-methylbutyrate supplementation
  • Vitamin D supplementation
  • Quality of life
  • Body composition
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 75 years.
  • Male and female participants.
  • Diagnosis of colon cancer at localized or locally advanced stages (TNM stages I-III).
  • Patients scheduled for primary surgical treatment.

Exclusion criteria

Exclusion Criteria:

  • disease (stage IV)
  • Diagnosis of rectal cancer or tumors involving the rectum
  • Prior chemotherapy or radiotherapy before surgery.
  • Presence of synchronous malignant tumors.
  • Pregnant or breastfeeding women.
  • Presence of severe medical conditions, including acute pancreatitis, severe liver or kidney disease, heart failure, severe pulmonary disease, or peripheral arterial disease affecting the lower limbs.
  • Diagnosis of anorexia nervosa or other severe eating disorders.
  • Known allergy or intolerance to any nutritional supplements used in the study.
  • Medical to moderate-to-vigorous physical activity.
  • Regular participation in high-intensity exercise programs.
  • High risk of poor adherence to the study procedures, as determined by the study team.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Standard nutritional care + supervised exercise program

    Participants receive postoperative standard nutritional care according to routine clinical practice and individualized nutritional assessment. In addition, they participate in a structured supervised exercise program including progressive resistance and functional exercises targeting major muscle groups, adapted to their clinical condition.

    Dietary Supplement: Standard hypercaloric-hyperproteic nutritional supplementation · Behavioral: Supervised exercise program

  • Experimental
    Enhanced nutritional supplementation + non-structured physical activity

    Participants receive postoperative enhanced nutritional supplementation, including beta-hydroxy beta-methylbutyrate (HMB) and vitamin D, in addition to standard nutritional care based on routine clinical practice and individualized nutritional assessment. Participants also receive general physical activity recommendations according to standard postoperative care without participation in a structured exercise program.

    Dietary Supplement: HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium · Behavioral: General physical activity recommendations

  • Experimental
    Enhanced Nutritional Supplementation + Supervised Physical Activity

    Participants receive postoperative enhanced nutritional supplementation, including beta-hydroxy beta-methylbutyrate (HMB) and vitamin D, in addition to standard nutritional care based on routine clinical practice and individualized nutritional assessment. In addition, they participate in a structured supervised exercise program including progressive resistance and functional exercises targeting major muscle groups, adapted to their clinical condition.

    Dietary Supplement: HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium · Behavioral: Supervised exercise program

  • Active comparator
    Standard nutritional care + general physical activity recommendations

    Participants receive postoperative standard nutritional care according to routine clinical practice and individualized nutritional assessment. Participants also receive general physical activity recommendations according to standard postoperative care without participation in a structured exercise program.

    Dietary Supplement: Standard hypercaloric-hyperproteic nutritional supplementation · Behavioral: General physical activity recommendations

Interventions

  • Dietary supplementStandard hypercaloric-hyperproteic nutritional supplementation

    Participants receive a standard oral nutritional supplementation consisting of a hypercaloric and hyperproteic formula designed to support recovery and nutritional status in patients undergoing surgery.

    Also known as: Standard Nutrition

  • Dietary supplementHMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium

    Participants receive an oral hypercaloric and hyperproteic nutritional supplementation enriched with β-hydroxy β-methylbutyrate (HMB) and supplemented with vitamin D and calcium. This formulation is designed to support muscle mass preservation and functional recovery in patients undergoing surgical treatment.

    Also known as: Enhanced Nutritional Supplementation

  • BehavioralSupervised exercise program

    Participants follow a structured and supervised physical activity program including resistance exercises and functional training. Physical activity levels are periodically monitored using wearable activity devices.

    Also known as: Supervised Physical Activity

  • BehavioralGeneral physical activity recommendations

    Participants receive general recommendations for physical activity according to routine clinical practice but do not participate in the structured supervised exercise program.

    Also known as: General Physical Activity

06

What researchers measure

Primary outcomes

  1. Change in phase angle (PhA)

    Phase angle will be assessed by bioelectrical impedance analysis (BIA) as a bioelectrical marker of nutritional and cellular status. Results will be expressed in degrees.

    Time frame: Baseline (first postoperative visit) and 6 months follow-up

  2. Change in quadriceps rectus femoris cross-sectional area

    Muscle mass will be assessed using nutritional ultrasound by measuring the cross-sectional area of the quadriceps rectus femoris at a standardized anatomical site (cm²).

    Time frame: Baseline (first postoperative visit) and 6 months follow-up

Secondary outcomes

  1. Plasma concentration of inflammatory and metabolic biomarkers measured by multiplex immunoassay

    Plasma concentrations of selected biomarkers (including adiponectin, FABP-3, FGF-21, BDNF, IL-6, IL-15, TNF-α, and MCP-1) will be measured using multiplex immunoassay technology (Bio-Plex MAGPIX / Luminex xMAP). Each biomarker will be analyzed as an individual continuous variable and expressed in pg/mL.

    Time frame: From baseline (first postoperative visit), 3 months and 6 months follow-up

  2. Percentage of DNA methylation in peripheral blood mononuclear cells (PBMCs)by quantitative PCR

    DNA methylation levels will be assessed in peripheral blood mononuclear cells (PBMCs) using bisulfite conversion followed by quantitative PCR. Results will be expressed as the percentage of methylated cytosines at CpG sites.

    Time frame: Baseline (first postoperative visit) and 6 months follow-up

  3. Change in urinary oxylipin concentrations by UHPLC-MS/MS

    Selected oxylipins, including isoprostanes, prostaglandins, and thromboxane, will be quantified in first-morning urine samples using targeted ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-QqQ-MS/MS). Results will be expressed as concentrations normalized to urinary creatinine (e.g., ng/mg creatinine).

    Time frame: Baseline (first postoperative visit) and 6 months follow-up

  4. Change in relative abundance of gut microbiota taxa

    Gut microbiota composition will be assessed in stool samples using 16S rRNA gene sequencing. Relative abundance of bacterial taxa will be quantified at different taxonomic levels (e.g., phylum, genus) and expressed as percentages (%) of total sequencing reads per sample.

    Time frame: Baseline (first postoperative visit) and 6 months follow-up

  5. Change in health-related quality of life score (EORTC QLQ-C30)

    Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores will be calculated according to standard scoring procedures and expressed on a scale from 0 to 100.

    Time frame: Baseline (first postoperative visit), 3 months, and 6 months follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — A decision regarding the sharing of individual participant data (IPD) has not yet been made. The study has received a favorable opinion from the relevant Research Ethics Committee. As described in the participant information and informed consent, data collected in this study are handled under strict confidentiality and in accordance with applicable data protection regulations, and are intended for research purposes within the scope of the project. If IPD is shared in the future, this would occur only in a de-identified format and upon reasonable request for scientific purposes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2027, 25 months after the start.

Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 25 months is below that.

Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2026
First posted
Apr 16, 2026
StartActual
Jul 1, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07534852
Lead sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Collaborators
Instituto de Salud Carlos III
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Jul 1, 2025
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Manuel Macías-González, PhD.
Contact
mmacias.manuel@gmail.com
+34 952 36 76 00
Libia Alejandra Garcia-Flores, PhD.
Contact
libia.garcia@ibima.eu
+34 952 36 76 00
Manuel Macías-Gonzalez, PhD
principal investigator · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Carolina Muriel-Lopez, PhD
principal investigator · Hospital Regional de Malaga

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion